Review Article

Lynch Syndrome and Endometrial Cancer

Authors: Sareena Singh, MD, Kimberly E. Resnick, MD

Abstract

In patients with Lynch syndrome, gynecologic cancer often can be the first presenting malignancy. In this review, we summarize the genetics of Lynch syndrome and review the various modalities of identifying patients at risk for this syndrome. The clinical characteristics of Lynch-associated endometrial cancer and screening and risk-reducing strategies also are described.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colon cancer. Obstet Gynecol 2005;105:569-574.
 
2. Lynch HT, Lynch JF. Lynch syndrome: history and current status. Dis Markers 2004;20:181-198.
 
3. Necochea R. From cancer families to HNPCC: Henry Lynch and the transformations of hereditary cancer, 1975-1999. Bull Hist Med 2007;81:267-285.
 
4. Lynch HT, Shaw MW, Magnuson CW, et al. Hereditary factors in cancer: study of two large Midwestern kindreds. Arch Intern Med 1966;117:206-212.
 
5. Seiden MV, Patel D, O’ MJ, et al. Case records of the Massachusetts General Hospital. Case 13-2007. A 46-year-old woman with gynecologic and intestinal cancers. N Engl J Med 2007;356:1760-1769.
 
6. Palomaki GE, McClain MR, Melillo S, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:42-65.
 
7. Koessler T, Oestergaard MZ, Song H, et al. Common variants in mismatch repair genes and risk of colorectal cancer. Gut 2008;57:1097-1101.
 
8. Turnpenny P, Ellard S. Emery’s Elements of Medical Genetics. 12th ed. New York:Elsevier;2005.
 
9. de la Chapelle A. Microsatellite instability. N Engl J Med 2003;349:209-210.
 
10. Vasen HF, Mecklin JP, Khan PM, et al. The international collaborative group on hereditary non-polyposis colorectal cancer (IGC-HNPCC). Dis Colon Rectum 1991;34:424-425.
 
11. Lipton LR, Johnson V, Cummings C, et al. Refining the Amsterdam criteria and Bethesda guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic. J Clin Oncol 2004;22: 4934-4943.
 
12. Syngal S, Fox EA, Eng C, et al. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000;9:641-645.
 
13. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999;116:1453-1456.
 
14. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-268.
 
15. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006;354:2751-2763.
 
16. Green RC, Parfrey PS, Woods MO, et al. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst 2009;101: 331-340.
 
17. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006;296:1479-1487.
 
18. Kastrinos F, Steyerberg EW, Mercado R, et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 2011;140:73-81.
 
19. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Dis Colon Rectum 2014;57:1025-1048.
 
20. McConechy MK, Talhouk A, Li-Chang HH, et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol 2015;137:306-310.
 
21. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007;107:159-162.
 
22. Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004;127:17-25.
 
23. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105-110.
 
24. Wang Y, Wang Y, Li J, et al. Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium. J Hematol Oncol 2013;6:22.
 
25. Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. J Clin Oncol 2007;25:5158-5164.
 
26. Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006;106:87-94.
 
27. Westin SN, Lacour RA, Urbauer DL, et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol 2008;26:5965-5971.
 
28. National Comprehensive Cancer Network. NCCN guidelines. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed May 29, 2015.
 
29. Committee on Practice Bulletins-Gynecology, Society of Gynecologic Oncology. ACOG Practice Bulletin no. 147: Lynch syndrome. Obstet Gynecol 2014;124:1042-1054.
 
30. Lu KH, Loose DS, Yates MS, et al. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res (Phila) 2013;6:774-781.
 
31. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354: 261-269.
 
32. Bast RC, Xu FJ, Yu YH, et al. CA 125: the past and the future. Int J Biol Markers 1998;13:179-187.
 
33. Powell JL, Hill KA, Shiro BC, et al. Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med 2005;50:585-590.
 
34. Yildiz A, Yetimalar H, Kasap B, et al. Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 2012;164:191-195.
 
35. Dotters DJ, Preoperative CA. 125 in endometrial cancer: is it useful? Am J Obstet Gynecol 2000;182:1328-1334.
 
36. Jiang T, Huang L, Zhang S. Preoperative serum CA125: a useful marker for surgical management of endometrial cancer. BMC Cancer 2015;15:396.